Pharmaceuticals, Biotechnology & Life Sciences

Insider buys 3,600 Rapport shares, signaling confidence in its CNS pipeline amid market swings and a shift toward value‑based reimbursement. Discover the impact.

Glenbrook Capital’s 30% stake in SenesTech signals confidence in its RNAi pest‑control platform, recent revenue lift, and potential medical‑device spin‑offs.

Insightful analysis of Roivant’s insider selling: understand why execs trade, what it means for investors, and how it could signal future upside or caution.

Insider buying at Rapport Therapeutics signals optimism amid a 10% drop; learn how a 0.3% stake could boost a 52‑week low stock.

Institutional investors pile into Surrozen, backing its FDA‑cleared retinal therapy and new AMD drug. 7.7% stake boosts confidence and may drive 2027‑2029 growth.

Dyne Therapeutics insider buy: CMO Kerr Douglas buys 8,000 shares and 12,000 RSUs, signaling long‑term optimism amid market volatility.

Merck insiders rebalancing shares—David Maraldo’s recent 401(k) filing shows a steady stake amid oncology wins and AI‑driven growth.

Qiming Corporate GP VI’s 1.7 M‑share sale of Alamar Biosciences fuels a $45 M liquidity boost, offering the biotech firm a chance to fund trials, cut debt or pursue acquisitions while keeping its long‑term value intact.

Enliven Therapeutics’ CFO buys at $14.85 and sells near $38.50, showing disciplined liquidity management and confidence in the company’s oncology growth.

Insightful analysis of CFO Ignelzi Troy A.’s recent 5,500‑share buy in Rapport Therapeutics and its impact on the company’s Phase‑2 success, cash runway, and future outlook.